The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Kimmtrak (tebentafusp), from Immunocore, intended for the treatment of uveal melanoma. Kimmtrak was reviewed under EMA’s accelerated assessment programme. Kimmtrak will be available as a 100 mcg/0.5 mL concentrate for solution for infusion.
Immunocore has announced trial results showing that overall survival (OS) was statistically significantly improved with IMCgp100 (tebentafusp) compared with investigator’s choice of therapy as treatment of patients with metastatic uveal melanoma in the phase III IMCgp100-202 study (NCT03070392).
AstraZeneca announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with...
Although cancer cells express antigens recognizable to the immune system, tumors employ a number of diverse mechanisms aimed at subverting the host anti-tumor immune response.
Immunocore announces that United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted a Market Authorisation Application (MAA) seeking the approval of tebentafusp (IMCgp100) for the treatment of patients with metastatic uveal melanoma (mUM).
Immunocore announced approval from the FDA of Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A 02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).
Immunocore Holdings plc ,a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases announces that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), the Therapeutic Goods Administration (TGA) in Australia and Health Canada have granted marketing authorization for Kimmtrak (tebentafusp) for the treatment of HLA-A02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase II trial of patients with relapsing multiple sclerosis (MS)
Background: Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity.
Immunocore announced that the European Commission (EC) has approved Kimmtrak (tebentafusp) for the treatment of HLA-A 02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).